secwatch.observer — SEC 8-K summary
======================================

Issuer:     NextCure, Inc. (NXTC)
CIK:        0001661059
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0001558370-23-008118
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NextCure reports Q1 net loss $16.1M, cash $145.5M; pipeline data expected Q4 2023
--------------------------------------------------------------------------------

- Net loss $16.1M for Q1 2023 vs $20.6M loss in Q1 2022, narrowing on lower R&D expenses.
- Cash $145.5M down from $159.9M; expects runway into mid-2025.
- Three clinical programs (NC410, NC762, NC525) data updates expected in Q4 2023.
- First patient dosed with NC525 (LAIR-1 mAb) Phase 1 in AML in Feb 2023.
- R&D expenses decreased to $11.6M from $15.0M YoY.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661059/000155837023008118/0001558370-23-008118-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661059/000155837023008118/nxtc-20230504x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-008118

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer